Sodium-glucose cotransporters 2 (SGLT2) inhibitors are a new class of oral anti-diabetic drugs that have played an increasingly important role in the management of type 2 diabetes in recent years (9–11). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.